Stocktoria
ORAMED PHARMACEUTICALS INC. ORMP
ORAMED PHARMACEUTICALS INC. (ORMP) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $2.0M at a 3202.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.495 |
| Retained earnings / assets | -0.535 |
| EBIT / assets | -0.065 |
| Equity / liabilities | 6.419 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ORMP | ORAMED PHARMACEUTICALS INC. | 2/9 | 7.8 | 3 | — |
| LPCN | Lipocine Inc. | — | — | — | -82.3% |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | 1/9 | 14.17 | — | — |
| CYCN | Cyclerion Therapeutics, Inc. | 1/9 | — | — | — |
| BIOE | Bio Essence Corp | 9/9 | — | 14.1 | — |
| CLSDQ | Clearside Biomedical, Inc. | 2/9 | — | — | — |
| RANI | Rani Therapeutics Holdings, Inc. | 4/9 | -4.67 | — | — |
About ORAMED PHARMACEUTICALS INC.
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
FAQ
Is ORMP financially healthy?
ORAMED PHARMACEUTICALS INC.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does ORMP pay a dividend?
No, ORAMED PHARMACEUTICALS INC. does not currently pay a dividend.
How profitable is ORMP?
In FY2025, ORAMED PHARMACEUTICALS INC. had a net margin of 3202.5% and a return on equity of 32.1%.
What is ORMP's P/E ratio?
ORAMED PHARMACEUTICALS INC.'s trailing price-to-earnings (P/E) ratio is about 3.0×, based on its latest annual earnings.
What is the analyst price target for ORMP?
The average Wall-Street price target for ORAMED PHARMACEUTICALS INC. is $6.25, about 46.4% above the recent price, from 1 analysts (consensus: strong buy).
Is ORMP a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on ORAMED PHARMACEUTICALS INC.: a Piotroski F-score of 2/9, an Altman Z″ in the safe zone, a P/E of about 3.0×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.